The role of cilostazol for peripheral arterial disease;Die rolle von cilostazol in der therapie der pAVK

Gefasschirurgie

Volumn 13, Issue 3, 2008, Pages 171-178

  Amendt, K ^a,c   Hsu, E ^a   Gomer, M ^a   Rumenapf G ^b  

^a Innere Medizin I

^b Diakonissen Stiftungs Krankenhaus   (Germany)

^c MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Atherothrombosis; Cilostazol; Conservative treatment; Intermittent claudication; PAD

Indexed keywords

ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1;

ARTERY DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; HEADACHE; HIGH RISK PATIENT; HUMAN; INTERMITTENT CLAUDICATION; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; WALKING;

EID: 45049088312     PISSN: 09487034     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00772-008-0595-7     Document Type: Review

References (44)

1. Agrawal NK, Maiti R, Dash D, Pandey BL (2007) Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res 56: 118-123
2. Ahn CW, Lee HC, Park SW et al. (2001) Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 52: 45-53
3. Ahn Y, Myung HL, Jeong WJ et al. (2008) Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients (CIDES-Trial). Circ J 72: 35-39
4. Amendt K (2005) PGE-1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 56: 409-415
5. Amendt K (2006) Ist der allgemein akzeptierte therapeutische Nutzen des Gehtrainings bei Patienten mit arterieller Verschlusskrankheit evidenzbasiert? Hämostaseologie 26: 224-228
6. arznei-telegramm (2007) Cilostazol (Pletal) bei Claudicatio intermittens. Jg 38: 27-28
7. Backer TLM de, Bogaert M, Vander Stichele R (2008) Buflomedil for intermittent claudication. Cochrane Database Syst Rev 1: CD000988
8. Beebe HG, Dawson DL, Cutler BS et al. (1999) A new pharmacological treatment for intermittent claudication. Arch Intern Med 159: 2041-2050
9. Beil W (2007) Cilostazol, ein neues Medikament zur Therapie der Claudicatio intermittens. Perfusion 20: 90-92
10. Chapman TM, Goa KL (2003) Cilostazol. A review of its use in intermittent claudication. Am J Cardiovasc Drugs 3: 117-138
11. Cone J, Wang S, Tandon N et al. (1999) Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 34: 497-504
12. Dawson DL, Cutler BS, Meissner MH, Strandness DE (1998) Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation 98: 678-686
13. Dawson DL, Christopher A, DeMaioribus Ryan T et al. (1999) The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 178: 141-146
14. Dawson DL, Cutler BS, Hiatt WR et al. (2000) A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109: 523-530
15. De la Haye R, Diehm C, Blume J et al. (1992) Eine epidemiologische Untersuchung zur Einsetzbarkeit und zu den Grenzen der physikalischen Therapie/Bewegungstherapie bei der arteriellen Verschlusskrankheit im Stadium II nach Fontaine. Vasa (Suppl) 38: 5-40
16. Diehm C, Schuster A, Allenberg J et al. (2004) High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients. Cross-sectional study. Atherosclerosis 172: 95-105
17. Diener HC, Cunha L, Forbes C (1996) European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1-13
18. Douglas JS, Holmes DR Jr, Kereiakes D et al. (2003) Cilostazol for restenosis trial: a randomized, double blind study following coronary artery stent implantation [abstract]. Circulation 108: 4
19. Douglas JS, Holmes DR Jr, Kereiakes D et al. (2005) Coronary stent restenosis in patients treated with cilostazol. Circulation 112: 2826-2832
20. Elam MB, Heckmann J, Crouse JR et al. (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18: 1942-1947
21. Goto S (2005) Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by low rate of bleeding. Atherosclerosis (Suppl 6) 6: 3-11
22. Gotoh F, Tohgi H, Hirai S et al. (2000) Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9: 147-157
23. Guest JF, Davie AM, Clegg JP (2005) Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in UK. Curr Med Res Opin 21: 817-826
24. Hiatt WR, Money SR, Brass EP (2008) Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 47: 330-336
25. Hirsch AT, Haskal ZJ, Hertzer NR et al. (2006) ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremities, renal, mesenteric, and abdominal aortic). Circulation 113: e463-e465
26. Hobbs SD, Marshall T, Fegan C et al. (2007) The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial. J Vasc Surg 45: 65-70
27. Iida O, Nanto S, Uematsu M et al. (2005) Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 69: 1256-1259
28. Inoue T, Kobayashi M, Uetsuka Y, Uchiyama S (2006) Pharmacoeconomic analysis of cilostazol for secondary prevention of cerebral infarction. Circ J 70: 453-458
29. Kim MJ, Park K-G, Lee K-M et al. (2005) Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 45: 552-556
30. Limbs International Medicinal Buflomedil (LIMB) Study Group (2008). Circulation 117: 816-822
31. Kwon SU, Cho YJ, Koo JS et al. (2005) Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter doubleblind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36: 782-786
32. Min PK, Jung JH, Ko YG et al. (2007) Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 71: 1685-1690
33. Money SR, Herd JA, Isaacsohn JL et al. (1998) Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27: 267-275
34. Nakamura N, Osawa H, Yamabe H et al. (2005) Effects of cilostazol on lipid and fatty acid metabolism. Clin Exp Med 4: 170-173
35. Norgren L, Hiatt WR, Dormandy LA et al. (2007) Inter-Society consensus for the management of peripheral arterial disease (TASC II). Eur J Endovasc Surg 33: 1-75
36. Oida K, Ebata K, Kanehara H et al. (2003) Effect of cilostazol on impaired vasodilatatory response to the brachial artery to ischemia in smokers. J Atheroscler Thromb 10: 93-98
37. Packer M, Carver R, Rodeheffer RJ et al. (1991) Effect of oral milrinone on mortality in sever chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475
38. Pratt CM, Camerota AJ (2001) New therapeutic options in the management of claudication. Am J Cardiol (Suppl) 87: 1D-43D
39. Robless P, Mikhailidis D, Stansby G (2008) Cilostazol for peripheral arterial disease. Cochrane Databas Syst Rev 1: CD003748
40. Schrör K (2002) The pharmacology of cilostazol. Diabetes Obes Metab (Suppl 2) 4: 14-19
41. Thompson PD, Zimet R, Forbes WP, Zhang P (2002) Meta-analysis of results from eight randomizes, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90: 1314-1319
42. Watanabe K, Ikeda S, Komatsu J et al. (2003) Effect of cilostazol on vascular reactivity in patients with vasospastic angina pectoris. Am J Cardiol 92: 21-25
43. Wilhite DB, Comerota AJ, Schmieder FA et al. (2003) Managing of PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38: 710-713
44. Zhang Z, Foster JK, Kolm P et al. (2006) Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 152: 770-774